Allogeneic adipose-derived stem cells
Phase 2Biologic
Allogeneic adipose-derived stem cells is one of 19 biologic programs targeting COVID-19. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
18
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1COVID-19 Vaccine
ModernaPreclinical
Singulair
AstraZenecaPreclinical
Activella
Eli LillyPreclinical
Proventil
Mylan Pharmaceuticals IncPreclinical
Nitrostat
VViatris Specialty LLC
Preclinical
SARS-COV-2 VACCINE
ModernaPreclinical
Achromycin V
WWyeth-Lederle Vaccines
Preclinical
Statins
SanofiPreclinical
Allogeneic adipose-derived stem cells
CCelltex Therapeutics Corporation
Phase 2
Disease-Modifying Anti-Rheumatic Drugs
RochePreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- CCelltex Therapeutics Corporation